ultrageny% Corporate Deck February 2022 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabil ...

ultrageny% Corporate Deck February 2022 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabil ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2021 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants Joshua Higa - Senior Director of Investor Relations Emil Kakkis - President, Chief Executive Officer & Director Erik Harris - Executive Vice President & Chief Commercial Officer Mardi Dier - Executive Vice President & Chief Financial Officer Camille Bedrosian - Chief Medical Officer & Executive Vice President Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Ba ...

ultrageny Corporate Deck November 2021 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabili ...

ultrageny Corporate Deck November 2021 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabili ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2021 Earnings Conference Call November 2, 2021 5:00 PM ET Company Participants Joshua Higa - Director of Investor Relations and Corporate Communications Emil Kakkis - President, Chief Executive Officer and Director Erik Harris - Executive Vice President and Chief Commercial Officer Mardi Dier - Executive Vice President and Chief Financial Officer Camille Bedrosian - Chief Medical Officer & Executive Vice President Conference Call Participants Tazeen Ahmad - Ba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File No. 001-36276 ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) Delaware 27-2546083 (State or oth ...

ultrageny Corporate Deck August 2, 2021 Legal Warning Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectations regarding our manufacturing capabil ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2021 Earnings Conference Call July 30, 2021 5:00 PM ET Company Participants Joshua Higa - Director, IR Emil Kakkis - President and CEO Erik Harris - Chief Commercial Officer Camille Bedrosian - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Joon Lee - Truist Securities Salveen Richter - Goldman Sachs Joseph Schwartz - SVB Leerink Cory Kasimov - JPMorgan Laura Chico ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the transition period from to . ULTRAGENYX PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Delaware 27-2546083 (State or other jurisdiction of incorporation or ...